AstraZeneca ’s Imfinzi meets primary endpoint in Phase III trial for stage III NSCLC

AstraZeneca and its biologics research and development arm MedImmune have reported positive results from the Phase III PACIFIC clinical trial of Imfinzi (durvalumab) to treat patients with locally advanced, unresectable (stage III) non-small-cell lun …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news